Merck And Dynavax Pair Up For Heplisav
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from international Phase III study of the novel hepatitis B vaccine remain on track for first half 2008, Dynavax CEO Dina says.
You may also be interested in...
Merck’s Heplisav Gets FDA Clinical Hold
Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.
Merck’s Heplisav Gets FDA Clinical Hold
Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.
Dynavax’ Heplisav Phase III Data Bolsters Hep B Seroprotection Claims
Long-term data from study comparing Heplisav to GSK's Engerix-B shows 100 percent seroprotection 50 weeks post-vaccination.